Kite to Highlight Industry-Leading CAR T-Cell Therapy Portfolio at ASH 2024, Including Positive Survival Outcomes in Both Clinical Trials and the Real-World [Yahoo! Finance]
Arcellx, Inc. (ACLX)
Company Research
Source: Yahoo! Finance
Multiple Myeloma to be Presented by Partner Arcellx; Follows Progress with First Patient Dosed in Phase 3 iMMagine-3 Study – – Survival Rate for Yescarta ® Supported by Largest Real-World Analysis of CAR T for Second-Line Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma – – Durability of Response and Long-Term Survival with Yescarta ® and Tecartus ® in Multiple Blood Cancers Observed in ZUMA-5, ZUMA-2, and ZUMA-3 Studies – SANTA MONICA, Calif., November 05, 2024 BUSINESS WIRE )--Kite, a Gilead Company (Nasdaq: GILD), will share 18 presentations, including six oral presentations, demonstrating the strength of its CAR T-cell therapy portfolio across a spectrum of blood cancers during the 66th American Society of Hematology (ASH) Annual Meeting and Exposition (December 7-10). "Our data underscore our commitment to helping people with blood cancers live longer and demonstrate the benefit of CAR T-cell therapy as a mainstay of blood cancer treatment," said Dominiq
Show less
Read more
Impact Snapshot
Event Time:
ACLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACLX alerts
High impacting Arcellx, Inc. news events
Weekly update
A roundup of the hottest topics
ACLX
News
- ASH 2024: Arcellx publishes positive results for Anito-cel in multiple myeloma [Yahoo! Finance]Yahoo! Finance
- Arcellx, Inc. (NASDAQ: ACLX) had its price target raised by analysts at UBS Group AG from $106.00 to $114.00. They now have a "buy" rating on the stock.MarketBeat
- Arcellx, Inc. (NASDAQ: ACLX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $115.00 price target on the stock.MarketBeat
- Arcellx, Inc. (NASDAQ: ACLX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $105.00 price target on the stock.MarketBeat
- Arcellx Announces New Positive Data for Its iMMagine-1 Study in Patients With Relapsed or Refractory Multiple Myeloma to be Presented During an Oral Presentation at the 66th ASH Annual Meeting and Exposition [Yahoo! Finance]Yahoo! Finance
ACLX
Earnings
- 11/7/24 - Beat
ACLX
Sec Filings
- 12/12/24 - Form 8-K
- 12/9/24 - Form 8-K
- 12/5/24 - Form 4
- ACLX's page on the SEC website